Trial reportStroke2018
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Role of histone deacetylases and sirtuins in the ischaemic stroke: a systematic review and meta-analysis of animal studies.Stroke and vascular neurology · 2026Pooled it
- Preclinical Evidence of Paeoniflorin Effectiveness for the Management of Cerebral Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis.Journal of thrombosis and haemostasis : JTH · 2026Article
- "The emerging role of lymphocytes in post-stroke inflammation: A treatable target and review of current pharmacological evidence in humans".Brain, behavior, & immunity - health · 2026Review
- Deciphering the disease ecosystem of ischemic stroke via multi-omics and prospects for therapeutic strategies.Frontiers in neuroscience · 2026Review
- Valproic acid boosts hair follicle stem cell resilience to oxygen-glucose deprivation through autophagy induction and AKT/mTOR suppression.Scientific reports · 2025Article
- The study of promoting the rational use of sodium valproate in the intensive care unit.Scientific reports · 2025Article
- Comparative Analysis of Systemic Inflammatory Biomarkers Across Multiple Antiseizure Medications: A Single-Center Retrospective Cohort Study of 1782 Patients.Journal of clinical medicine · 2025Article
- Association of migraine treatments with reduced ischemic stroke risk: Evidence from two large-scale real-world data analyses.Headache · 2025Article
- Role of histone deacetylases and sirtuins in the ischaemic stroke: a protocol for a systematic review and meta-analysis of animal studies.Stroke and vascular neurology · 2025Article
- Potential therapeutic targets for ischemic stroke in pre-clinical studies: Epigenetic-modifying enzymes DNMT/TET and HAT/HDAC.Frontiers in pharmacology · 2025Review
- Ischemic Stroke and the Biological Hallmarks of Aging.Aging and disease · 2024Review
- Epigenetic modifiers as inducer of bioactive secondary metabolites in fungi.Biotechnology letters · 2024Review
- Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management.Current neuropharmacology · 2024Review
- Post-stroke depression: epigenetic and epitranscriptomic modifications and their interplay with gut microbiota.Molecular psychiatry · 2023Review
- Transient plasticity response is regulated by histone deacetylase inhibitor in oxygen-glucose deprivation condition.Pharmacological reports : PR · 2023Article
- SUMOtherapeutics for Ischemic Stroke.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Genomics in Treatment Development.Advances in neurobiology · 2023Article
- Epigenetic mechanisms and potential therapeutic targets in stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Review
- SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Rebecca L BrookesFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Siobhan CrichtonFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Charles D A WolfeFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Qilong YiFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Linxin LiFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Graeme J HankeyFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Peter M RothwellFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).
Hugh S MarkusFrom the Stroke Research Group, Clinical Neurosciences, University of Cambridge, United Kingdom (R.L.B., H.S.M.); Division of Health and Social Care Research, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (S.C., C.D.A.W.); National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario (Q.Y.); School of Medicine and Pharmacology, The University of Western Australia, Perth (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Western Australian Neuroscience Research Institute, Perth (G.J.H.); and Stroke Prevention Research Unit, Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.). hsm32@medschl.cam.ac.uk.
Canadian Blood Services · CASir Charles Gairdner Hospital · AUUniversity of Cambridge · GBPerron Institute for Neurological and Translational Science · AUUniversity of Western Australia · AU
Funding
British Heart Foundation PG/13/30/30005Wellcome Trust
Abstract
background and purposeA variant in the histone deacetylase 9 (
methodsData were pooled from 3 prospective studies recruiting patients with previous stroke or transient ischemic attack and long-term follow-up: the South London Stroke Register, The Vitamins to Prevent Stroke Study, and the Oxford Vascular Study. Patients receiving SVA were compared with patients who received antiepileptic drugs other than SVA using survival analysis and Cox Regression.
resultsA total of 11 949 patients with confirmed ischemic event were included. Recurrent stroke rate was lower in patient taking SVA (17 of 168) than other antiepileptic drugs (105 of 530; log-rank survival analysis
conclusionsThese results suggest that exposure to SVA, an inhibitor of HDAC, may be associated with a lower recurrent stroke risk although we cannot exclude residual confounding in this study design. This supports the hypothesis that HDAC9 is important in the ischemic stroke pathogenesis and that its inhibition, by SVA or a more specific HDAC9 inhibitor, is worthy of evaluation as a treatment to prevent recurrent ischemic stroke.
Indexed as
Brain IschemiaRegistriesStrokeAgedAged, 80 and overAnticonvulsantsDisease-Free SurvivalFemaleFollow-Up StudiesHistone Deacetylase InhibitorsHistone DeacetylasesHumansMaleMiddle AgedRepressor ProteinsRisk FactorsAnticonvulsantsHDAC9 protein, humanHistone Deacetylase InhibitorsHistone DeacetylasesRepressor ProteinsValproic Acidgeneticshistone deacetylasesecondary preventionsodium valproatestrokesurvival analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.